Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
US8003661B2 · kind B2 · utility
1Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2008 |
| Grant date | Aug 23, 2011 |
| Priority date | — |
| Expiry date | Mar 25, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.